Published • loading... • Updated
Sedivention raises €2.9M to treat obesity with a one-time alternative to Ozempic
Summary by Tech Funding News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Sedivention raises €2.9M to treat obesity with a one-time alternative to Ozempic
Sedivention, a medtech startup from Germany, has secured €2.9 million in seed funding to develop a minimally invasive, one-time outpatient treatment for obesity. The funding round was led by bmp Ventures and IBG funds. Other investors include High-Tech Gründerfonds, superangels, Cambridge Ventures, and the strategic investment arm of a global medtech company that has not been named. Sedivention, founded in Magdeburg in 2021 by Dr Ute Nollert and…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
